Ursodeoxycholic acid therapy in children with cholestatic liver disease
The beneficial effect of ursodeoxycholic acid have been documented in adults but experience with this agent is limited in the pediatric population. The objective of this study was to evaluate ursodeoxycholic acid treatment in children with cholestatic liver disease. Twenty-four patients with intr...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hacettepe University Institute of Child Health
1999-01-01
|
| Series: | The Turkish Journal of Pediatrics |
| Subjects: | |
| Online Access: | https://turkjpediatr.org/article/view/3203 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850028843183636480 |
|---|---|
| author | Gönül Dinler Nurten Koçak Aysel Yüce Figen Gürakan Hasan Özen |
| author_facet | Gönül Dinler Nurten Koçak Aysel Yüce Figen Gürakan Hasan Özen |
| author_sort | Gönül Dinler |
| collection | DOAJ |
| description |
The beneficial effect of ursodeoxycholic acid have been documented in adults but experience with this agent is limited in the pediatric population. The objective of this study was to evaluate ursodeoxycholic acid treatment in children with cholestatic liver disease.
Twenty-four patients with intrahepatic cholestasis (neonatal hepatitis 7, Byler disease 7, idiopathic intrahepatic cholestasis 10) whose ages ranged from 1.5 months to 15 years were treated with ursodeoxycholic acid (15-20 mg/kg/day) for 12 months. Liver biopsy was performed initially on all patients and on 17 at the end of the twelve months. The outcome was evaluated by monitoring clinical and biochemical markers of cholestasis, including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum fasting bile acids and total and conjugated bilirubin at entry and every three months of treatment.
Pruritus was ameliorated in all patients; there was complete disappearance of itching in 16.7 percent. There were significant decreases in mean serum levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin and gamma-glutamyl transpeptidase. Liver biopsy specimens showed a significant improvement in the cholestasis but not in fibrosis. No adverse effects of therapy were noted.
The improvements in the clinical and biochemical parameters and tolerability of the drug suggest that ursodeoxycholic acid is a safe and effective treatment in children with intrahepatic cholestasis.
|
| format | Article |
| id | doaj-art-3e3bca6a851d41d58633ecd8124decca |
| institution | DOAJ |
| issn | 0041-4301 2791-6421 |
| language | English |
| publishDate | 1999-01-01 |
| publisher | Hacettepe University Institute of Child Health |
| record_format | Article |
| series | The Turkish Journal of Pediatrics |
| spelling | doaj-art-3e3bca6a851d41d58633ecd8124decca2025-08-20T02:59:42ZengHacettepe University Institute of Child HealthThe Turkish Journal of Pediatrics0041-43012791-64211999-01-0141110.24953/turkjpediatr.1999.3203Ursodeoxycholic acid therapy in children with cholestatic liver diseaseGönül Dinler0Nurten Koçak1Aysel Yüce2Figen Gürakan3Hasan Özen4Hacettepe University Faculty of MedicineHacettepe University Faculty of MedicineHacettepe University Faculty of MedicineHacettepe University Faculty of MedicineHacettepe University Faculty of Medicine The beneficial effect of ursodeoxycholic acid have been documented in adults but experience with this agent is limited in the pediatric population. The objective of this study was to evaluate ursodeoxycholic acid treatment in children with cholestatic liver disease. Twenty-four patients with intrahepatic cholestasis (neonatal hepatitis 7, Byler disease 7, idiopathic intrahepatic cholestasis 10) whose ages ranged from 1.5 months to 15 years were treated with ursodeoxycholic acid (15-20 mg/kg/day) for 12 months. Liver biopsy was performed initially on all patients and on 17 at the end of the twelve months. The outcome was evaluated by monitoring clinical and biochemical markers of cholestasis, including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum fasting bile acids and total and conjugated bilirubin at entry and every three months of treatment. Pruritus was ameliorated in all patients; there was complete disappearance of itching in 16.7 percent. There were significant decreases in mean serum levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin and gamma-glutamyl transpeptidase. Liver biopsy specimens showed a significant improvement in the cholestasis but not in fibrosis. No adverse effects of therapy were noted. The improvements in the clinical and biochemical parameters and tolerability of the drug suggest that ursodeoxycholic acid is a safe and effective treatment in children with intrahepatic cholestasis. https://turkjpediatr.org/article/view/3203childrenursodeoxycholic acidcholestatic liver disease |
| spellingShingle | Gönül Dinler Nurten Koçak Aysel Yüce Figen Gürakan Hasan Özen Ursodeoxycholic acid therapy in children with cholestatic liver disease The Turkish Journal of Pediatrics children ursodeoxycholic acid cholestatic liver disease |
| title | Ursodeoxycholic acid therapy in children with cholestatic liver disease |
| title_full | Ursodeoxycholic acid therapy in children with cholestatic liver disease |
| title_fullStr | Ursodeoxycholic acid therapy in children with cholestatic liver disease |
| title_full_unstemmed | Ursodeoxycholic acid therapy in children with cholestatic liver disease |
| title_short | Ursodeoxycholic acid therapy in children with cholestatic liver disease |
| title_sort | ursodeoxycholic acid therapy in children with cholestatic liver disease |
| topic | children ursodeoxycholic acid cholestatic liver disease |
| url | https://turkjpediatr.org/article/view/3203 |
| work_keys_str_mv | AT gonuldinler ursodeoxycholicacidtherapyinchildrenwithcholestaticliverdisease AT nurtenkocak ursodeoxycholicacidtherapyinchildrenwithcholestaticliverdisease AT ayselyuce ursodeoxycholicacidtherapyinchildrenwithcholestaticliverdisease AT figengurakan ursodeoxycholicacidtherapyinchildrenwithcholestaticliverdisease AT hasanozen ursodeoxycholicacidtherapyinchildrenwithcholestaticliverdisease |